Bayer is weighing legal action and Novartis has expressed concern at plans by doctors in the north of England to defy official guidance by using a cancer medicine as a cheap eye drug.
Daiichi Sankyo announced that its Phase III ENLIVEN trial of pexidartinib met its primary endpoint.
X-Spine Systems, a division of Xtant Medical Systems, is shutting down a facility in Ohio and terminating 54 people between December and February 2018.
Amgen and Kirin Holdings decided to dissolve their joint venture, Kirin-Amgen, which will become a wholly owned subsidiary of Amgen.
New Jersey sued Purdue Pharma LP, maker of the chronic pain medication OxyContin, accusing the company of engaging in deceptive marketing practices that contributed to what it called the state’s opioid crisis.
Shares of Voyager Therapeutics fell more than 12 percent in premarket trading after the company announced Sanofi Genzyme walked away from its $845 million gene therapy treatment for Parkinson’s disease.
AstraZeneca stepped up its bet on immunotherapy combo treatments to fight lung cancer by signing a deal with Incyte as they will start a final-stage study in 2018.
A large group of U.S. states accused key players in the generic drug industry of a broad price-fixing conspiracy, moving to widen an earlier lawsuit to add many more drugmakers and medicines in an action that sent some company shares tumbling.
Pfizer Inc.’s third-quarter profit beat market estimates and the company raised its full-year 2017 earnings forecast.
Merck announced that the company pulled its application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer from the European Medicines Agency.
Kymera Therapeutics launched with a $30 million Series A financing. The round was led by Atlas Venture, which co-founded, seeded and incubated the company, along with Lilly Ventures and Amgen Ventures.
Publicis Health announced the integration of Publicis LifeBrands Medicus (PLBM) into Saatchi & Saatchi Wellness (SSW) to create a new Wellness Intelligence-driven agency designed to help health and wellness-oriented audiences navigate the expanding “Wellness Culture.”
Endo International Plc forecast earnings for the third quarter well above analysts’ estimates amid a lawsuit filed by it against U.S. health regulators that seeks to protect the drugmaker’s blood pressure drug franchise.
U.S. shareholder activists are addressing a soaring death toll from opioid drug abuse, asking companies that make and distribute the painkillers to review the risks their businesses could face from their role in the sector.
Mereo BioPharma agreed a licensing deal and acquisition option for a rare disease drug from AstraZeneca as the big drugmaker continues to divest non-core assets.
Novartis agreed to buy French-based Advanced Accelerator Applications (AAA) for $3.9 billion, giving it a platform in radiopharmaceuticals and access to a new therapy for the kind of cancer that killed Steve Jobs.
Sumitomo Dainippon Pharma Co. Ltd. and Poxel SA announced the signing of a strategic partnership for the development and commercialization of Imeglimin – an investigational therapeutic agent for type 2 diabetes – in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. Poxel is a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders.
Wave Life Sciences officially opened a new state-of-the art manufacturing facility to support advancement of the company’s stereopure nucleic acid platform.
AbbVie expect its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago.
Merck & Co. reported profit ahead of Street estimates on strong sales of its cancer drug Keytruda, but total revenue fell in third-quarter 2017 from disruptions due to the NotPetya cyber attack and loss of market share for many of the company’s older drugs.